CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)

被引：0
|
作者：
Riess, H.
Neuhaus, P.
Post, S.
Gellert, K.
Ridwelski, K.
Schramm, H.
Zuelke, C.
Fahlke, J.
Langrehr, J.
Oettle, H.
机构：
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [41] Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
    Cognetti, F.
    Ruggeri, E. M.
    Felici, A.
    Gallucci, M.
    Muto, G.
    Pollera, C. F.
    Massidda, B.
    Rubagotti, A.
    Giannarelli, D.
    Boccardo, F.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 695 - 700
  • [42] CHEMOTHERAPY IN PANCREATIC-CANCER - RESULTS OF A CONTROLLED, PROSPECTIVE, RANDOMIZED, MULTICENTER TRIAL
    MALLINSON, CN
    RAKE, MO
    COCKING, JB
    FOX, CA
    CWYNARSKI, MT
    DIFFEY, BL
    JACKSON, GA
    HANLEY, J
    WASS, VJ
    BRITISH MEDICAL JOURNAL, 1980, 281 (6255): : 1589 - &
  • [43] Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01)
    Hagiwara, Yasuhiro
    Ohashi, Yasuo
    Uesaka, Katsuhiko
    Boku, Narikazu
    Fukutomi, Akira
    Okamura, Yukiyasu
    Konishi, Masaru
    Matsumoto, Ippei
    Kaneoka, Yuji
    Shimizu, Yasuhiro
    Nakamori, Shoji
    Sakamoto, Hirohiko
    Morinaga, Soichiro
    Kainuma, Osamu
    Imai, Koji
    Sata, Naohiro
    Hishinuma, Shoichi
    Ojima, Hitoshi
    Yamaguchi, Ryuzo
    Hirano, Satoshi
    Sudo, Takeshi
    EUROPEAN JOURNAL OF CANCER, 2018, 93 : 79 - 88
  • [44] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [45] Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC
    Di Costanzo, Francesco
    Gasperoni, Silvia
    Manzione, Luigi
    Bisagni, Giancarlo
    Labianca, Roberto
    Bravi, Stefano
    Cortesi, Enrico
    Carlini, Paolo
    Bracci, Raffaella
    Tomao, Silverio
    Messerini, Luca
    Arcangeli, Annarosa
    Torri, Valter
    Bilancia, Domenico
    Floriani, Irene
    Tonato, Maurizio
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (06): : 388 - 398
  • [46] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
    Yoshitomi, Hideyuki
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Ohtsuka, Masayuki
    Kato, Atsushi
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Okamura, Daiki
    Suzuki, Daisuke
    Nakajima, Masayuki
    Aida, Toshiaki
    Miyazaki, Masaru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] RANDOMIZED PHASE III TRIAL COMPARING ADJUVANT PACLITAXEL/GEMCITABINE/CISPLATIN (PGC) TO OBSERVATION IN PATIENTS WITH RESECTED INVASIVE BLADDER CANCER: RESULTS OF THE SOGUG-GUO-AEU 99/01 TRIAL
    Solsona, E.
    Paz-Ares, L.
    Fernandez, J. M.
    Hevia, M.
    Orsola, A.
    Morote, J.
    Bellmunt, J.
    De La Rosa, F.
    Llorente, C.
    Donas, Jl
    Guillem, V
    Cozar, J. M.
    Ballesteros, P.
    Javaloyas, J.
    Carbonero, J.
    Burgues, J. P.
    Rodriguez Molina, J.
    Gutierrez, J. L.
    Garcia, D.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 212 - 212
  • [48] Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
    Conroy, T.
    Hammel, P.
    Turpin, A.
    Belletier, C.
    Wei, A.
    Mitry, E.
    Lopez, A.
    Francois, E.
    Artru, P.
    Biagi, J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Bouche, O.
    Lambert, A.
    Monard, L.
    Rat, P.
    Castan, F.
    Bachet, J. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1334 - S1334
  • [49] Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
    Conroy, Thierry
    Hammel, Pascal
    Hebbar, Mohamed
    Ben Abdelghani, Meher
    Wei, Alice Chia-chi
    Raoul, Jean-Luc
    Chone, Laurence
    Francois, Eric
    Artru, Pascal
    Biagi, James Joseph
    Lecomte, Thierry
    Assenat, Eric
    Faroux, Roger
    Ychou, Marc
    Volet, Julien
    Sauvanet, Alain
    Jouffroy-Zeller, Claire
    Rat, Patrick
    Castan, Florence
    Bachet, Jean-Baptiste
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [50] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4121 - 4122
12345